Castelhano
Arlindo Castelhano, New York, NY US
Patent application number | Description | Published |
---|---|---|
20080261943 | PYRROLOPYRIMIDINE A2B SELECTIVE ANTAGONIST COMPOUNDS, THEIR SYNTHESIS AND USE - The subject invention provides compounds having the structure: | 10-23-2008 |
Arlindo L. Castelhano, Farmingdale, NY US
Patent application number | Description | Published |
---|---|---|
20080221153 | N3-SUBSTITUTED IMIDAZOPYRIDINE C-KIT INHIBITORS - Compounds represented by Formula (I): | 09-11-2008 |
Arlindo L. Castelhano, New City, NY US
Patent application number | Description | Published |
---|---|---|
20080221187 | N-substituted pyrazolyl-amidyl-benzimidazolyl c-Kit inhibitors - Compounds represented by Formula (I): | 09-11-2008 |
20090062275 | N-Substituted Imidazopyridine c-Kit Inhibitors - Compounds represented by Formula (I): | 03-05-2009 |
20090082369 | Pyrrolo[2,3d]pyrimidine compositions and their use - This invention pertains to compounds having the structure: | 03-26-2009 |
20090192177 | 2-ARYL pyrrologpyrimidines for A1 and A3 receptors - This invention pertains to compounds which specifically inhibit the adenosine A | 07-30-2009 |
20110015197 | mTOR INHIBITOR SALT FORMS - Salt forms of mTOR inhibitors of the Formula (I): | 01-20-2011 |
20130123501 | PROCESS FOR THE PREPARATION OF THE COMPOUND OSI-906 - Process for preparing the tyrosine kinase inhibitor OSI-906 comprises coupling Compound (2) with Compound (6) under specified conditions. | 05-16-2013 |
20130158264 | Polymorphs of OSI-906 - Polymorphic forms of the tyrosine kinase inhibitor OSI-906, preparation, pharmaceutical compositions, and uses thereof. The invention includes methods of treating diseases such as cancer, including cancer mediated at least in part by IGF-1 R and/or IR, with the polymorphs and compositions. This Abstract is not limiting of the invention. | 06-20-2013 |